==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1219 which contains 1 entries.


Entry 1
(1) Primary information
ID1829
ThPP IDTh1219
Therapeutic Peptide/Protein NameAnti-thymocyte Globulin (Rabbit)
SequenceNA view full sequnce in fasta
Functional ClassificationIIIb
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)61 °C (FA
Half Life 2-3 days, may increase after multiple doses administration
DescriptionRabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
Indication/DiseaseFor prevention of renal transplant rejection
PharmacodynamicsAntithymocyte Globulin (ATG) is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. ATG reduces the host immune response against tissue transplants or organ allografts.
Mechanism of ActionBinds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis.
Toxicity Not known whether ATG (rabbit) distributes into human milk; however, other immunoglobulins are distributed into human milk.
MetabolismMost likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production.
AbsorptionT-cell depletion usually observed within 1 day after initiating therapy. Average 21.5 and 87 mcg/mL 4–8 hours post-infusion after first and last IV doses, respectively, when given for 7–11 days.
Volume of DistributionNA
ClearanceNA
CategoriesAntibody
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionThe risk or severity of adverse effects can be increased with combination of drugs like BCG, Denosumab, Fingolimod, G17DT, GI-5005, INGN 201, INGN 225, Leflunomide, Natalizumab, Pimecrolimus.
TargetT-cell surface glycoprotein CD1a, Major histocompatibility complex class I-related gene protein, Integrin alpha-L, T-lymphocyte activation antigen CD86, Low affinity immunoglobulin gamma Fc region receptor II-b, T-cell surface glycoprotein CD4, Integrin beta-1, Integrin alpha-V, Integrin beta-3
Information of corresponding available drug in the market
Brand NameATG-Fresenius
CompanyGenzyme Inc.
Brand DiscriptionATG-Fresenius S 20 mg/ml concentrate for solution for infusion.
Prescribed forATG-Freseniusis usually used in combination with other immunosuppressive drugs(corticosteroids,azathioprine,cyclosporineA,etc.) to suppress the immune system and thus preventing rejection following organ transplantation.
Chemical NameNA
FormulationOne ml of the concentrate contains 20 mg anti-human T-lymphocyte immunoglobulin from rabbits
Physcial AppearanceConcentrate for solution for infusion.
Route of Administration Intravenous
Recommended DosageOne ml of the concentrate contains 20 mg anti-human T-ddiThe recommended dose range is 2 to 5 mg/kg/d ATG - Fresenius S. The most common doses are in the range of 3 to 4 mg/kg/ dlymphocyte immunoglobulin from rabbits
ContraindicationHypersensitivity to the active substance or to any of the excipients
Side Effectsbladder pain,chest pain,chills
Useful Linkhttp://www.pharmaline.co.il/images/newsletterregistration/neopharm/2012/11052012/atgdr.pdf
PubMed ID24907357, 25672649, 12783210, 25243624
3-D StructureTh1219 (View) or (Download)